Pharmena

1-MNA small molecule · Atherosclerosis, NASH

Overview

Developing the endogenous metabolite 1-methylnicotinamide (1-MNA) as a small-molecule therapeutic for atherosclerosis and metabolic-liver disease, alongside a nutraceutical business.

What they do

Pharmena S.A. is a Polish biotechnology company built around the patented active substance 1-methylnicotinamide (1-MNA), an endogenous metabolite of vitamin B3. The company pursues a dual model: clinical-stage drug development of 1-MNA for cardiometabolic indications, and a commercial nutraceutical and dermocosmetic business that already generates revenue and helps fund R&D. Pharmena is listed on the Warsaw Stock Exchange (formerly NewConnect, ticker PHR).

Lead program & status

The lead asset is the small molecule 1-MNA, positioned for atherosclerosis and metabolic-liver disease (NASH/MASH). Pharmena has historically run early clinical work on 1-MNA's anti-atherosclerotic and anti-inflammatory effects and has sought pharmaceutical partners by presenting accumulated data. More recently the company has explored additional 1-MNA applications, including a reported assessment of efficacy in psoriasis run with the Medical University of Łódź (results reported in a current filing in early 2026) and conceptual work on a medical device for hard-to-heal wounds (announced 2024). Specific efficacy outcomes for the cardiometabolic programs remain limited publicly.

Why it matters

1-MNA is an unusually well-tolerated endogenous molecule, giving Pharmena a differentiated safety story in crowded metabolic-disease markets. As of 2024 the strategy hinges on out-licensing the drug candidate while the consumer-health products sustain the business.

FAQ

What is 1-MNA?

1-MNA (1-methylnicotinamide) is an endogenous metabolite of vitamin B3 that Pharmena develops as a small-molecule therapeutic with anti-inflammatory and anti-atherosclerotic properties.

Is Pharmena publicly listed?

Yes. Pharmena S.A. trades on the Warsaw Stock Exchange under the ticker PHR, having originated on the NewConnect market.

What indications is 1-MNA targeted at?

The core focus is atherosclerosis and metabolic-liver disease (NASH/MASH); the company has also reportedly explored 1-MNA in psoriasis and wound care.

Company website / source ↗ Open the interactive map →